US 11,717,500 B2
Treatment of spondyloarthritis
Anders Björk, Bjärred (SE); and Gunnar Hedlund, Lund (SE)
Assigned to PHARMACYL AB, Bjarred (SE)
Filed by PHARMACYL AB, Bjärred (SE)
Filed on Jan. 26, 2021, as Appl. No. 17/158,117.
Claims priority of application No. 20155130 (EP), filed on Feb. 3, 2020.
Prior Publication US 2021/0236441 A1, Aug. 5, 2021
Int. Cl. A61K 31/167 (2006.01); A61P 19/02 (2006.01)
CPC A61K 31/167 (2013.01) [A61P 19/02 (2018.01)] 17 Claims
 
1. A method for the treatment a disease resulting from spondyloarthritis by administering, to a mammal in need of such treatment, a therapeutically effective amount of a compound of formula (I)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or solvate thereof; wherein
R1 is selected from C1-C6 alkyl and C3-C6 cycloalkyl;
R2 is selected from hydrogen and C1-C3 alkyl;
R3, R4, R5, and R6 are independently selected from hydrogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, fluoro, chloro, and bromo, wherein any alkyl is optionally substituted with one or more fluoro;
R7 is selected from hydrogen and C1-C3 alkyl;
R8 and R9 are independently selected from C1-C6 alkyl.